Significance of the serum level of transforming growth factor β1 and its difference in patients with chronic hepatitis B and HBV-induced hepatic cirrhosis

He Ze-Bao,Zhu Jian-Sheng,Chen Zhi,Zhu Min,Zeng Wen-Xin,Chen Hua-Zhong,Wang Geng-Ge,Fang Hao
DOI: https://doi.org/10.3969/j.issn.1009-3079.2007.29.009
2007-01-01
World Chinese Journal of Digestology
Abstract:AIM: To investigate the relationship between the levels of transforming growth factor (TGF) β1 in serum and inflammation, as well as fibrous degeneration of the liver, and the difference in the levels of TGFβ1 in patients between with chronic hepatitis B and HBV-induced hepatic cirrhosis. METHODS: Four markers of hepatic fibrosis (HA, LN, CIV, PC III) were measured by radioimmunoassay and the serum levels of TGFβ1 were measured by enzyme linked immunosorbent assay (ELISA) in 65 patients with chronic hepatitis B (chronic hepatitis group), 56 patients with HBV-induced hepatic cirrhosis (hepatic cirrhosis group) and 50 health personnel who were negative for HBV markers (control group). RESULTS: The serum level of TGFβ1 in the chronic hepatitis group was significantly higher than that in the hepatic cirrhosis and control groups (22 ± 13 μg/L vs 10 ± 9 μg/L, 11 ± 9 μg/L, P < 0.01). The level of TGFβ1 in the hepatic cirrhosis group was similar to that in the control group. There was no correlation between the serum level of TGFβ1 and hepatic function, as well as markers of hepatic fibrosis. However, PC III was excluded, and the coefficient of correlation between PC III and serum level of TGFβ1 in the hepatic cirrhosis group (r = 0.269, P = 0.045). CONCLUSION: TGFβ1 may play an important role in the onset of hepatic cirrhosis, and it may aid diagnosis of hepatic cirrhosis. However, there is no evidence to show that it can help establish the degree of inflammation and fibrous degeneration in the liver.
What problem does this paper attempt to address?